Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pcDNA-NCF2 is a recombinant DNA expression plasmid designed to overexpress the Neutrophil Cytoplasmic Factor 2 (NCF2) protein in mammalian cells. NCF2, also known as p67-phox, is a critical cytosolic subunit of the NADPH oxidase complex, which is responsible for the generation of reactive oxygen species (ROS). In the context of cardiovascular research, pcDNA-NCF2 is utilized as a molecular tool to investigate the pathological role of NCF2 upregulation in endothelial dysfunction. Studies have demonstrated that overexpression of NCF2 via this plasmid inhibits the PI3K/Akt/Nrf2 signaling pathway, thereby promoting ferroptosis and inflammatory responses in human umbilical vein endothelial cells (HUVECs). It is primarily used in preclinical research to model the progression of atherosclerosis and to validate the mechanism of action of potential therapeutic agents that target the NCF2-mediated oxidative stress pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pcDNA-NCF2.